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Abstract: Chronic pain affects approximately 1 in 5 people in Europe, and around half 
of sufferers receive inadequate pain management. The most common location is the lower 
back. Pharmacological treatment of this condition is challenging because of the range of 
causative mechanisms and the difficulty of balancing analgesic efficacy and tolerability. An 
international panel of clinical pain specialists met in September, 2009, to discuss the treat-
ment of chronic low back pain, and to review preclinical and clinical data relating to the new 
analgesic, tapentadol. A lack of consensus exists on the best treatment for low back pain. The 
range of regularly prescribed pharmacological agents extends from nonopioids (paracetamol, 
NSAIDs, and COX-2 inhibitors) to opioids, antidepressants and anticonvulsants. Pain relief 
may be compromised, however, by an undetected neuropathic component or intolerable side 
effects. Treatment is potentially life-long and effective analgesics are urgently needed, with 
demonstrable long-term safety. Combining separate agents with different mechanisms of action 
could overcome the limitations of present pharmacological therapy, but clinical evidence for 
this approach is currently lacking. Tapentadol combines µ-opioid agonism with noradrenaline 
reuptake inhibition in a single molecule. There is strong evidence of synergistic antinociception 
between these two mechanisms of action. In preclinical and clinical testing, tapentadol has 
shown efficacy against both nociceptive and neuropathic pain. Preclinical data indicate that 
tapentadol’s µ-opioid agonism makes a greater contribution to analgesia in acute pain, while 
noradrenaline reuptake inhibition makes a greater contribution in chronic neuropathic pain 
models. Tapentadol also produces fewer adverse events than oxycodone at equianalgesic doses, 
and thus may have a ‘µ-sparing effect’. Current evidence indicates that tapentadol’s efficacy/
tolerability ratio may be better than those of classical opioids. However, further research is 
needed to establish its role in pain management.
Keywords: chronic low back pain, neurophysiological changes, neuropathic component, 
multimechanistic approach, efficacy/side effect ratio, tapentadol
Introduction
Chronic pain represents a major healthcare problem which seriously impairs the qual-
ity of sufferers’ working and social lives, and the most common single location is the 
lower back.1 Chronic low back pain (LBP) is difficult to treat because of the range of 
causative mechanisms that may be involved; this difficulty is compounded by the lim-
ited efficacy of current pharmacological agents, and exemplified by the inconsistency 
of existing treatment patterns. Moreover, optimal pain management demands not only 
effective pain relief, but a precise balance of analgesia, tolerability, and beneficial 
effect on functionality/quality of life.
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In September 2009, an international panel of clinical 
pain specialists met to discuss the challenges of chronic 
LBP, and to review the preclinical and clinical data relating 
to the new analgesic agent, tapentadol, which may offer a 
novel treatment option for chronic LBP. Based on a literature 
search of PubMed before the meeting, 20 unique articles 
were chosen by the moderator for presentation to the panel. 
Other presentations came from articles relating to the changes 
occurring in chronic LBP and the preclinical and clinical 
testing of tapentadol, as well as data on file from completed 
clinical trials.
Prevalence of low back pain
A 2006 survey of 46,394 adults in 15 European countries 
and Israel found that 19% of respondents suffered from 
moderate to severe chronic pain ($5 on a 10-point Numeric 
Rating Scale [NRS]) and nearly half received inadequate 
pain management.1 Other surveys in Norway2 and Denmark3 
have produced similar results. The economic implications for 
society are significant in terms of the utilization of healthcare 
resources.4
In the pan-European study, the most common location 
of chronic pain was the back, in 47% of sufferers (5% upper 
back, 18% lower back, 24% unspecified).1 This finding is 
consistent with other sources of prevalence data on low 
back pain, indicating an overall prevalence of 80.5 per 
1000 population.5 It affects more women than men and the 
prevalence increases with age.5,6 In the US, LBP accounts 
for almost 30 million physician visits per year–56% of 
which are to primary care physicians.7 Thus LBP imposes a 
significant economic burden. In Sweden alone, the cost of 
LBP in 2001 was estimated to be €1860 million,8 while in 
the US the overall cost of back pain is estimated to exceed 
US$15 billion per year.9
Complexity of treating low back pain
LBP is defined as pain located in the lumbosacral region 
of the spine, the most frequent location being the fourth 
and fifth lumbar segment. It may be classified according to 
its etiology; mechanical or nonspecific LBP has no serious 
underlying pathology or nerve root compromise, in contrast 
to secondary LBP.10 It may also be classified according to its 
duration into 1 of 3 phases: acute, subacute (intermittent), or 
chronic. Definitions vary, but LBP is generally regarded as 
chronic if symptoms persist for more than 3 to 6 months.11 
The transition to chronic LBP involves structural and neu-
rophysiological changes, such as peripheral and central 
sensitization.12 At this point the patient’s symptoms may 
be exacerbated by psychosocial factors such as irritability, 
 emotional distress, social withdrawal, excessive consumption 
of alcohol or medication, and loss of income.13 The result may 
be persistent disability, depression, or anxiety. The impact on 
quality of life is considerable.14 Early diagnosis is therefore 
important, to incorporate these aspects of the condition into 
the management of low back pain and increase the chance 
of recovery.15
Discussion
Despite the substantial economic burden of chronic LBP, 
there is a lack of consensus on the best treatment.16 Patients 
have very different levels of impairment, disability, and 
chronicity. Cases of low impairment and disability may best 
be treated by simple evidence-based therapies  – exercises, 
cognitive-behavioral interventions, and medication – but the 
multimechanistic nature of more severe chronic LBP means 
that no single intervention is likely to be effective.12,17
The complexity of treatment is further increased because 
chronic LBP may present with nociceptive pain, neuropathic 
pain, or both components.18,19 One survey using the painDE-
TECT questionnaire found that 37% of chronic LBP patients 
suffered from neuropathic pain, while 35% had nociceptive 
pain and results for the remaining patients were unclear.20 
A neuropathic component can complicate diagnosis for several 
reasons.21 Firstly, the signs and symptoms can vary between 
patients and within individual patients over time. The clinical 
picture may be obscured by psychosocial factors, which need to 
be addressed. This is important because neuropathic pain often 
fails to respond to commonly prescribed analgesic therapy,21 
treatment with single agent drugs being limited by incomplete 
efficacy and dose-limiting adverse effects.22
The major pharmacological agents currently used on-
label to treat chronic LBP include nonopioids, such as par-
acetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), 
cyclooxygenase-2 (COX-2) inhibitors, and opioids, while 
antidepressants, anticonvulsants, and local anesthetics may 
also be prescribed. However, any benefit can be adversely 
affected by several factors. For example, efficacy may be 
limited by an undetected neuropathic component, and poor 
tolerability may lead to an unfavorable efficacy/side effect 
ratio. Opioid-related side effects, in particular, affect 73% 
to 90% of patients treated for longer than 3 months and are 
directly responsible for high withdrawal rates of 20% to 
40%.23 Treatment may also be compromised by drug–drug 
interactions or the development of tolerance, demonstrating 
the urgent need for analgesics which are effective and safe 
in long-term use.
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These limitations can be addressed by combining agents 
with different mechanisms of action, to produce additive 
or synergistic analgesic effects and minimize drug-induced 
adverse events.24 This multimechanistic approach takes into 
account the diversity of underlying pain mechanisms and 
the different pharmacological principles required for their 
successful treatment. However, such polypharmacy also 
presents challenges. It reduces the convenience of treatment, 
and thus compliance, and creates the potential for pharma-
cokinetic drug–drug interactions.25 These may increase side 
effects or reduce analgesia, and the elderly, in particular, may 
be at increased risk.25 Therefore the safety and efficacy of 
specific combinations must be empirically evaluated,22 but 
up to now clinical study data are inadequate. An alternative 
multimechanistic approach is to develop novel compounds 
which possess multiple mechanisms of action.
The pharmacology of tapentadol
Tapentadol (see Table 1) has been developed to have broad 
analgesic activity by combining known analgesic principles 
(µ-opioid receptor agonism and noradrenaline reuptake 
inhibition) in a single molecule, and to offer a better balance 
between efficacy and tolerability than classical opioids. An 
immediate release formulation has recently been registered 
in the US to treat moderate to severe acute pain, and both 
immediate and prolonged formulations are currently under-
going registration in Europe for the treatment of severe acute 
and chronic pain.
Tapentadol’s agonistic activity at the µ-opioid receptors 
of afferent pain fibres inhibits the release of excitatory neu-
rotransmitters, and reduces the upward transmission of pain 
signals. Via its µ-opioid action in the brain, tapentadol also 
influences the release of neurotransmitters by the descend-
ing pain pathways, producing a further inhibition of pain.26 
Like other systemic opioids, tapentadol acts at all these 
sites and its overall analgesic effect is enhanced by synergy 
between them.27
Opioids can be effective in chronic neuropathic pain, but 
decreased potency requires higher doses in order to achieve 
sufficient analgesia.28,29 This characteristic of neuropathic pain, 
and the development of tolerance, both potentially increase 
the incidence of side effects. Tapentadol addresses this prob-
lem by virtue of its second analgesic mechanism of action, 
ie, noradrenaline reuptake inhibition, particularly in chronic 
neuropathic pain. This property has been reported by stud-
ies in a number of animal models.30 Noradrenaline reuptake 
inhibition exerts its antinociceptive effect via the descending 
pain pathways, where the increased synaptic noradrenaline 
binds to α-2 receptors and thereby reduces pain signals to the 
brain.31 There is strong evidence of synergistic antinociception 
between this mechanism of action and µ-opioid agonism.32–35
Other analgesic agents also possess more than 1 mecha-
nism of action; for example, at first sight the established 
weak opioid tramadol appears similar to tapentadol, since it 
is a µ-opioid receptor agonist which also affects the mono-
aminergic system. However, there are important differences. 
Both tapentadol’s mechanisms of action reside in a single 
molecule that is metabolized via O‑glucuronidation to an 
inactive metabolite.36 By contrast, tramadol is a racemic 
mixture of 2 enantiomers and produces an active metabolite. 
While the (–)-enantiomer and (+)-enantiomer of the parent 
compound produce noradrenaline reuptake inhibition and 
serotonin reuptake inhibition, respectively, weak µ-opioid 
receptor agonism resides mainly in the (+)-enantiomer of 
O‑desmethyl-tramadol, the major active metabolite. Thus, the 
relative contribution of the different mechanisms of action to 
the overall analgesic effect changes over time.36 As the parent 
molecule is metabolised, noradrenaline reuptake inhibition 
and serotonin reuptake inhibition diminish, and µ-opioid 
receptor agonism increases. This produces a complex time- 
and metabolism-dependent pattern of pharmacological 
activities.36 By contrast, tapentadol does not rely on meta-
bolic activation to achieve full µ-opioid receptor agonism. 
Also, tramadol is metabolized mainly by the cytochrome 
P450 system, which is polymorphic in humans, so that ‘poor 
metabolizers’ do not experience satisfactory analgesia with 
standard doses.36 Further differences favoring tapentadol over 
tramadol are that evidence suggests that analgesia is more 
readily obtained by noradrenaline reuptake inhibition than 
by serotonin reuptake inhibition.36,37
Tapentadol: preclinical testing
Despite having an affinity to the µ-opioid receptor 50 times 
lower than that of morphine, in vivo testing in rats and mice 
found that intravenous tapentadol was only 2 to 3 times less 
potent than morphine in acute nociceptive pain.36,37 In 2 animal 
models of chronic neuropathic pain it was broadly equipotent 
to morphine, despite this much lower binding affinity, which is 
Table 1 Properties of tapentadol
Chemical formula C14H23nO ⋅ HCl
Molecular weight 257.80
Racemic mixture no (single enantiomer)
Primary metabolic pathway Phase ii glucuronidation
Active metabolites no
Mechanism of action µ-opioid receptor agonist/
noradrenaline reuptake inhibitor
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important in terms of opioid side effects.36 Thus noradrenaline 
reuptake inhibition may make a greater contribution to the 
analgesic efficacy of tapentadol in chronic pain than in acute 
pain. This hypothesis is supported by a study which combined 
tapentadol with either the µ-opioid antagonist naloxone or the 
α-2 antagonist yohimbine.30 In Figure 1, the dose-response 
curve shifted much further to the right when the µ-opioid 
action of tapentadol was antagonised in acute pain. In chronic 
pain, however, the reverse applied; antagonizing noradrena-
line reuptake inhibition had the greater effect.30
Low affinity for the µ-opioid receptor and the presence 
of noradrenaline reuptake inhibition suggest that tapentadol 
might produce fewer opioid-related side effects than classical 
µ-opioid receptor agonists. The emetic potential of tapent-
adol and morphine has been compared in ferrets; tapentadol 
produced fewer retches and vomits per animal, and the dura-
tion of these effects was shorter.37 In mice, tapentadol had a 
weaker inhibitory effect than morphine on gastrointestinal 
motility.37 When the development of tolerance was investi-
gated in rats, complete tolerance was significantly delayed 
(P , 0.0001) in animals receiving tapentadol (23 days) 
compared with those receiving morphine (10 days).36
To summarise, tapentadol’s µ-opioid action decreased 
ascending pain messages as well as increasing pain inhibi-
tion via the descending pathways. Simultaneous blocking of 
the noradrenaline transporter further enhanced its analgesic 
effects via the increased activation of α-2 receptors. Thus there 
is a possible synergy between the mechanisms of action and 
also the sites of action. Because its distinct pharmacological 
profile differentiates tapentadol from other centrally acting 
analgesics, it has been proposed that tapentadol should be 
classified by its 2 mechanisms of action, µ-opioid  receptor 
agonism (MOR) and noradrenaline reuptake inhibition (NRI), 
as a MOR-NRI compound.38
Tapentadol: clinical trials in chronic LBP
Tapentadol has been subject to an extensive testing program; 
to date, around 8000 patients have participated in Phase 
III clinical trials with either the immediate-release (IR) 
or prolonged-release (PR) formulation. Chronic LBP was 
1 major pain model used in the phase III clinical program 
and has been included in the current phase IIIB program, 
to gather further evidence on the use of tapentadol in this 
prevalent chronic pain condition.
To evaluate the efficacy and safety of multiple doses of 
tapentadol PR, 981 patients with chronic LBP were recruited 
to a double-blind, randomized, active- and placebo- controlled, 
phase III study.39 A 3-week titration phase allowed patients 
to achieve their optimal individual dose of tapentadol PR 
(100–250 mg twice a day), oxycodone controlled release (CR; 
20–50 mg twice a day), or placebo. During the following 
12-week maintenance phase, patients were not permitted rescue 
medication but were allowed to adjust their dosage, to reflect 
clinical practice. The primary endpoint was the mean change in 
pain intensity at week 12 or over the entire 12-week period, using 
the last observation carried forward (LOCF) imputation.
Demographic and baseline characteristics were consistent 
across treatment groups, the majority of subjects being women 
and below 65 years of age.39 Severe pain (NRS $ 6) was reported 
by 88.5% of subjects and 53.4% had prior opioid experience.
0.3 1 3 10 30 100
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Low intensity tail flick 
(acute pain model)
Vehicle + Tapentadol iv
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%
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Yohimbine 2.5 mg/kg ip + Tapentadol iv
Figure 1 Differential contribution of µ-opioid agonism and noradrenaline reuptake inhibition in acute and chronic neuropathic pain models.30 in acute pain, 
antagonizing µ-opioid agonism with naloxone moves the dose–response curve further to the right than antagonizing noradrenaline reuptake inhibition with yohimbine, 
showing that µ-opioid agonism makes a greater contribution to the compound’s analgesic effect. in chronic neuropathic pain, the opposite is true; noradrenaline reuptake 
inhibition contributes more to analgesia.
Reprinted from European Journal of Pain, vol 14, issue 8. Schröder W, De Vry J, Tzschentke TM, Jahnel U, Christoph T. Differential contribution of opioid and noradrenergic 
mechanisms to the antinociceptive and antihypersensitive efficacy of tapentadol in rat models of nociceptive and neuropathic pain, 814–821, Copyright (2010), with permission 
from Elsevier.
Abbreviation: MPE, maximum possible effect.
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As can be seen from Figure 2, both active treatment 
groups produced a comparable, statistically significant, 
reduction in pain intensity over the maintenance period 
(both P , 0.001 vs placebo).39 Reductions were similar in 
opioid-naïve and opioid-experienced subjects. The results 
for tapentadol were supported by most secondary outcome 
parameters and also by more conservative imputations, such 
as worst observation carried forward (WOCF) and baseline 
observation carried forward (BOCF).39 Tapentadol also per-
formed significantly better than placebo in all categories of 
the Brief Pain Inventory, in overall sleep quality ratings and 
in the Patients’ Global Impression of Change (PGIC).39
Tapentadol was well tolerated, the incidence of typi-
cal opioid adverse events being approximately half that of 
oxycodone.39 At dosages providing similar analgesic effects, 
tapentadol produced numerically lower levels of constipation 
(13.8% vs 26.8%), nausea (20.1% vs 34.5%), vomiting (9.1% 
vs 19.2%), dizziness (11.9% vs 17.1%) and pruritis (7.2% vs 
16.8%).39 CNS effects tended to be milder in the tapentadol 
group than the oxycodone group.39 These tolerability findings 
are consistent with tapentadol having a ‘µ-sparing effect’, 
owing to the contribution of the NRI component.
Figure 3 shows the percentage of patients in the differ-
ent treatment groups who discontinued treatment over the 
study period. The main cause of discontinuation in the active 
treatment groups was treatment-emergent adverse events, 
predominantly gastrointestinal side effects. Discontinuations 
for this reason were lower in the tapentadol group than the 
oxycodone group, the disparity being particularly marked 
during the titration phase.39
The efficacy of tapentadol in treating purely neuropathic 
pain has been investigated in 395 patients suffering from 
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Figure 2 Average pain intensity scores over time.39 Pain relief was consistent during 
the maintenance period for both active treatment groups. Tapentadol PR significantly 
reduced mean pain intensity compared with placebo at week 12 and throughout the 
maintenance period, using the last observation carried forward imputation method 
for missing values.
Used with permission of informa Healthcare, from Expert Opinion on Pharmacotherapy, 
Buynak R, et al, Vol 11, issue 11, 2010; permission conveyed through Copyright Clear-
ance Center, inc.
Abbreviations: CR, controlled release; PR, prolonged release.
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Figure 4 Weekly average pain intensity scores.40 During the double-blind 
maintenance period, the mean pain intensity increased in the placebo group but 
remained stable in the tapentadol PR group. Tapentadol PR also showed a favorable 
tolerability profile, with a maximum of about 20% for individual adverse events.
Used with permission of informa Healthcare, from Current Medical Research 
and Opinion, Schwartz S, et al, Vol 27, issue 1, 2011; permission conveyed through 
Copyright Clearance Center, inc.
Abbreviations: OL, open label; DB, double blind; PR, prolonged release.
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Figure 3 Treatment discontinuations over time.39 The time to discontinuation in 
the tapentadol PR group was significantly longer than in the oxycodone CR group 
(P , 0.001), but not significantly different from that in the placebo group (P = 0.309). 
The primary reason for treatment discontinuation in the active treatment groups 
was adverse events (16.7% of the tapentadol PR group, compared with 32.3% of the 
oxycodone CR group).
Used with permission of informa Healthcare, from Expert Opinion on Pharmacotherapy, 
Buynak R, et al, Vol 11, issue 11, 2010; permission conveyed through Copyright Clear-
ance Center, inc.
Abbreviations: CR, controlled release; PR, prolonged release.
painful diabetic neuropathy.40 After a 3-week open-label 
titration phase, subjects who responded to tapentadol were 
assigned in a 1:1 ratio to receive either tapentadol PR or pla-
cebo for a 12-week, fixed-dose, double-blind phase. Rescue 
medication was allowed during this phase, and the doses of 
tapentadol spanned the entire therapeutic range, from 100 mg 
twice a day to 250 mg twice a day. The primary endpoint was 
to show a statistically significant difference in pain inten-
sity between tapentadol and placebo at week 12, using an 
11-point NRS and the LOCF imputation. This was achieved 
(P , 0.001) (see Figure 4) and efficacy was confirmed 
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by more conservative analyses of the primary endpoint, 
including BOCF, WOCF, and the proportions of patients 
showing $30% and $50% improvement.40
Long-term safety has been evaluated in a Phase III, 
open-label, randomized, active-controlled study.41 A total 
of 1117 patients with chronic LBP or osteoarthritis were 
randomised (4:1) to receive tapentadol PR or oxycodone 
CR. A 1-week titration phase enabled subjects to determine 
their optimal dose of analgesic, within the range of 100 to 
250 mg twice a day for tapentadol PR, or 20 to 50 mg twice 
a day for  oxycodone CR. This was followed by a 51-week 
maintenance phase, during which patients were encouraged 
to stay on a stable dose, but could adjust it if necessary, and 
were allowed paracetamol rescue medication. The primary 
endpoint was to determine the safety of tapentadol over 
1 year.41
The majority of subjects were women and under 65 years 
of age. Around two-thirds suffered from chronic LBP. At 
baseline, 89.4% had severe pain and the median pain intensity 
was 8.0 on an 11-point NRS. Approximately half the patients 
were opioid-naïve.
The mean dose of tapentadol for those who completed 
the study remained unchanged over the 1-year period.41 
Figure 5B shows that the mean pain intensity also remained 
unchanged, indicating that tapentadol produced a consistent 
reduction in pain over the total study period. There were 
fewer gastrointestinal and CNS adverse events in patients 
receiving tapentadol than in those receiving oxycodone.42 
Fewer patients in the tapentadol group withdrew from 
treatment because of adverse events (Figure 5A), and fewer 
patients in the tapentadol group discontinued treatment 
for any reason.42 In this study, therefore, the tolerability of 
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Figure 5 Discontinuations and mean pain intensity scores over time in patients suffering from low back pain and osteoarthritis.41,42 A) The percentage of patients who 
discontinued treatment because of adverse events was lower for tapentadol than for oxycodone (22.7% vs 36.8%). The overall percentage of patients who discontinued 
treatment was also lower for tapentadol than for oxycodone (53.8% vs 65%). B) Tapentadol PR provided sustainable relief of moderate to severe chronic knee or hip 
osteoarthritis or low back pain for up to 1 year. The efficacy of tapentadol PR was comparable to that of oxycodone CR.
Figure 5B from Pain Practice, Vol 10, Wild et al. Copyright © 2010 by John Wiley & Sons, inc. Reprinted by permission of John Wiley & Sons, inc; permission conveyed 
through Copyright Clearance Center, inc.
Abbreviations: CR, controlled release; PR, prolonged release; TEAEs, treatment-emergent adverse events.
tapentadol was superior to that of oxycodone over a period 
of 1 year.
In these clinical trials, tapentadol provided reliable 
analgesia in chronic LBP, comparable to that of oxycodone, 
a representative traditional opioid. It was effective against 
both nociceptive and neuropathic pain. At equianalgesic 
doses, tapentadol produced a lower incidence of side effects 
than oxycodone, leading to fewer patients withdrawing from 
treatment. Clinical studies in patients with acute and chronic 
osteoarthritis pain, and with acute postoperative pain, 
have produced similar results.41,43,44 Further clinical trials 
are currently under way comparing tapentadol with other 
analgesics.
Conclusion
The treatment of chronic LBP is challenging for  various 
 reasons, and requires a multidisciplinary approach to 
 treatment, encompassing pharmacological, psychological, 
and physical therapies. The efficacy of classical opioids 
can be compromised by dose restrictions as a result of side 
effects or the development of tolerance. Tapentadol com-
bines µ-opioid receptor agonism and noradrenaline reuptake 
inhibition in a single molecule, with the object of achieving 
an ‘opioid-sparing’ effect, that is, to produce fewer opioid-
related side effects for a given level of analgesia.
To date, preclinical and clinical data support the phar-
macological classification of tapentadol as an MOR-NRI30,38 
and suggest that its efficacy/tolerability ratio may be better 
than those of classical opioids.36,37,39,41 Further research is 
required, however, particularly into efficacy and safety in 
patients with pure neuropathic pain and to provide specific 
data on LBP with a neuropathic component. Comparisons 
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are also required between tapentadol and classical opioids 
other than oxycodone.
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